• Skip to main navigation
  • Skip to main content
  • Skip to Footer
  • Navigate Novartis
    • Patients
    • Healthcare Professionals
    • Media
    • Investors
    • Partners
    • ESG
    • Job Seekers
    • Clinical Trials
  • Coronavirus
  • Global
    • Novartis site directory
Novartis logo: a global healthcare company
  • Our Company
    • Our Leadership
      • Board of Directors
      • Executive Committee of Novartis
    • Our Approach
      • Strategy
      • Corporate Responsibility
      • Diversity & Inclusion
      • Partnering
      • People and Culture
    • Our Business
      • Global Product Portfolio
      • Innovative Medicines
      • Novartis Pharmaceuticals
      • Novartis Gene Therapies
      • Novartis Oncology
      • Sandoz
    • Media
      • Newsroom
      • News Archive
      • Multimedia Resources
      • Subscribe to Updates
    • Investors
      • Event Calendar
      • Financial Data
      • Share Data & Analysis
      • Shareholder Information
      • Environmental, Social & Governance
  • Our Focus
    • Disease Areas
      • Cancer
      • Cardiovascular, Renal and Metabolic Medicine
      • Immunology & Dermatology
      • Ophthalmology
      • Neuroscience
      • Respiratory
    • Platforms and Technology
      • Data and Digital
      • Cell & Gene Therapy
    • Novartis Stories
      • Discovery
      • From Our Labs
      • Access to Healthcare
      • Patient Perspectives
      • People and Culture
      • Live Magazine
  • Our Impact
    • Building Trust with Society
      • Corporate Responsibility
      • Ethical Standards
      • Access
      • Environmental Sustainability
    • Global Health
      • Malaria
      • Sickle Cell Disease
      • Chagas disease
      • Leprosy
      • Novartis Foundation
    • ESG Performance and Reporting
      • Materiality Assessment
      • Environmental, Social and Governance
      • Transparency and Disclosures
      • Positions on Key Topics
      • Statements on Key Issues
  • Our Science
    • Research & Early Development
      • Novartis Institutes for BioMedical Research
      • Research Disease Areas
      • Postdoc Program
      • Open Source Science
    • Drug Development at Novartis
      • Novartis Pipeline
      • Clinical Trials
      • Translational Medicine
      • Global Product Portfolio
    • Science Stories
      • Discovery
      • From Our Labs
  • Careers
    • Your Career
      • Global Career Search
      • Teams and Skills
      • Gene Therapies Careers
    • Working at Novartis
      • Diversity & Inclusion
      • People and Culture
      • Corporate Responsibility
    • Career Programs
      • Our Career Programs
      • Students and Scholars
      • Novartis Quantitative Sciences Hackathon
Search
  • TwitterTweet
  • FacebookShare
  • Share
    • Twitter
    • Facebook
    • LinkedIn
    • Email
    • Whatsapp
  • Jump to Comments
Stories/Patient Perspectives

Can better measurement lead to better outcomes? A look at NEDA4 in relapsing MS

Addressing four measures of disease progression in relapsing MS could help preserve physical and cognitive function.

May 17, 2015

Approximately 2.3 million people worldwide are living with multiple sclerosis (MS), a chronic disorder of the central nervous system. Relapsing MS – also known as RMS – is the most common form of the disease, characterized by attacks (relapses) where there is a sudden appearance of previous and/or new symptoms.

How to measure disease progression in RMS

Until now, doctors have only been looking at three measures of disease progression: relapses, MRI lesions and disability progression. But there’s a new measure that’s helping doctors and patients alike better assess if a treatment is working for them.

We’re also looking at brain shrinkage, or brain volume loss, to assess whether a patient is progressing in his or her disease. And when all four key measures of disease activity are effectively impacted, the patient is said to have reached a status of “no evidence of disease activity” (NEDA4).

Imagine you’re living with RMS and you finally hear those words – “no evidence of disease activity.” It’s a great example of how measurement can help us deliver effective treatments.

Measures of efficacy and why they matter

Measures of efficacy are evolving in RMS too, and if addressed, they could have a tremendous effect on what matters most to patients: their physical and cognitive function.

Our job doesn’t stop when we manufacture medicines. In fact, it’s just beginning. The impact of those medicines – their ability to positively change the course of disease in the people we treat – is critically important to how we assess the efficacy of treatments and the direction of our research and development moving forward. Most importantly, this impact is what matters to patients. After all, we all want treatments that make us feel better.

But how we measure the efficacy of a treatment evolves over time, and it is important to keep advancing the way we look at a medicine’s ability to maintain a patient’s quality of life and slow disease progression.

See for yourself why NEDA4 matters here:

Relapsing MS

Tags: 
Chronic Illness, Diseases, Living With Disease, Neuroscience
    • TwitterTweet
    • FacebookShare
    • Share
      • Twitter
      • Facebook
      • LinkedIn
      • Email
      • Whatsapp
    • Jump to Comments
  • Print
  • Save

Novartis Stories

View all

A couple showing each other data on their phones
Patient Perspectives

Digital innovation looks set to dominate the 2021 healthcare agenda

A woman, accompanied by her caregiver, shares her experiences with a doctor.
Patient Perspectives

Turning the sound up on patient voices in lung cancer research and development

Chinese family embracing exercise and the outdoors
Patient Perspectives

AI Nurse evolving for health failure patients in China

You are here

  1. Home ›
  2. Stories ›
  3. Patient Perspectives

Novartis Global

  • Navigate Novartis

    • Patients & Caregivers
    • Healthcare Professionals
    • Investors
    • Media
    • Society & ESG
    • Partners
  • Contact Us

    • Global Contacts
    • Office Locations
    • For Investors
    • For Media
  • About Novartis

    • Our Company
    • Our Focus
    • Our Impact
    • Our Science
    • Our Stories
  • Our Portfolio

    • Global Product Portfolio
    • Global Clinical Pipeline
  • Careers

    • Career Search

Connect with Novartis

  • twitter
  • linkedin
  • youtube
  • facebook
  • instagram
Novartis Site Directory
© 2021 Novartis AG
  • Terms of Use
  • Privacy Policy
  • Contact Us
  • Site Map
  • Cookie Settings

This site is intended for a global audience.